ReviewAmerican journal of physiology. Heart and circulatory physiology2017
Psoriasis as a human model of disease to study inflammatory atherogenesis.
Review in American journal of physiology. Heart and circulatory physiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Oxidized low-density lipoprotein associates with cardiovascular disease by a vicious cycle of atherosclerosis and inflammation: A systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Assessment and Clinical Relevance of Serum IL-19 Levels in Psoriasis and Atopic Dermatitis Using a Sensitive and Specific Novel Immunoassay.Scientific reports · 2019Trial
- Trial
- Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial.Circulation. Cardiovascular imaging · 2018Trial
- Bidirectional Inflammatory Mechanisms and Hematological/Coagulation Dysregulation in Psoriasis Complicated with Atherosclerosis: A Retrospective Hospital-Based Case-Control Study Leveraging the SH-YIMED Clinical Database.Psoriasis (Auckland, N.Z.) · 2026Article
- Cardiovascular Risk in Autoimmune Diseases: Mechanisms, Management, and Emerging Evidence.Cureus · 2025Review
- Serum Beta-Defensin-2 is a biomarker for psoriasis but not subclinical atherosclerosis: Role of IL17a, PI-3 kinase and Rac1.JEADV clinical practice · 2024Article
- Association between atherosclerosis and the development of multi-organ pathologies.SAGE open medicine · 2024Review
- Anti-inflammatory effect of biologic therapy in patients with psoriatic disease: A prospective cohort FDG PET study.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Cholesterol efflux capacity is associated with lipoprotein size and vascular health in mild to moderate psoriasis.Frontiers in cardiovascular medicine · 2023Article
- Prediction and verification of the effect of psoriasis on coronary heart disease based on artificial neural network.Heliyon · 2022Article
- IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis.International journal of molecular sciences · 2022Article
- PET/CT-Based Characterization of 18F-FDG Uptake in Various Tissues Reveals Novel Potential Contributions to Coronary Artery Disease in Psoriatic Arthritis.Frontiers in immunology · 2022Article
- Heightened splenic and bone marrow uptake ofAtherosclerosis · 2021Observational
- New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies.The Journal of investigative dermatology · 2021Review
- Impaired Coronary Blood Flow in Patients with Psoriasis: Findings from an Observational Cohort Study.The Journal of investigative dermatology · 2021Observational
- Anti-Inflammatory and Proliferative Properties of Luteolin-7-O-Glucoside.International journal of molecular sciences · 2021Article
- Psoriasis and Cardiometabolic Diseases: The Impact of Inflammation on Vascular Health.Psoriasis (Auckland, N.Z.) · 2021Review
- Application of machine learning to determine top predictors of noncalcified coronary burden in psoriasis: An observational cohort study.Journal of the American Academy of Dermatology · 2020Observational
- Relationship between chronic stress-related neural activity, physiological dysregulation and coronary artery disease in psoriasis: Findings from a longitudinal observational cohort study.Atherosclerosis · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Inflammation is known to play a significant role in the process of atherogenesis and cardiovascular disease (CVD). Indeed, patients with chronic inflammatory diseases are at increased risk for cardiovascular events. However, the mechanisms linking chronic inflammation and CVD remain poorly understood. Psoriasis, a chronic inflammatory skin disease associated with a greater risk of early cardiovascular events, provides a suitable human model to study the pathophysiology of inflammatory atherogenesis in humans. Additionally, cytokines such as TNF-α, IL-17A, and other immune pathways are the common links between the pathogenesis of psoriasis and atherosclerosis, and hence the approved treatments for psoriasis, which include selective cytokine inhibition (e.g., anti-TNF, anti-IL-17A, and anti-IL-12/23) and immune modulation (e.g., methotrexate or cyclosporine), provide an opportunity to examine the effect of modulating these pathways on atherogenesis. We have been using this human model in a large, prospective cohort study, and this review summarizes our approach and results of using this human model to study inflammatory atherogenesis. Specifically, we review simultaneous multimodal imaging of several vascular beds using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.